AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval from the FDA for a lung cancer indication, seven months after ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...